New RT journal calls for papers
Practical Radiation Oncology, a quarterly journal from ASTRO, is now accepting manuscripts.
Practical Radiation Oncology, a quarterly journal from ASTRO, is now accepting manuscripts. Manuscripts should focus on imaging, contouring, target delineation, simulation, treatment planning, immobilization, organ motion, patient safety, and quality measurement.
W. Robert Lee, MD, has been named editor of Practical Radiation Oncology. Dr. Lee is a professor in the department of radiation oncology and program director of the radiation oncology training program at Duke University in Durham, N.C. Visit ees.elsevier.com/practicalradonc/ to submit a manuscript.
Articles in this issue
PSA test drives diagnosis within families
New RT journal calls for papers
Oral Bisphosphonates Not Linked to Esophageal Cancer Risk
Partnering of chemotherapy and radiation yields great response rates in H&N ca, but has not improved survival
Should radiation therapy plus hormone therapy be the new standard of care for locally advanced prostate cancer?
Zoledronic acid plus standard therapy offers anticancer effect in multiple myeloma
Ipilimumab put on fast track by FDA
Who's News
ASTRO releases breast RT guide
Research chair named after Dr. Salem
Breast Cancer Specialists Brace for FDA Word on Avastin
Influx of Funding Impels Collaborative Explorations to Study Sarcoma as Behavior Model for Other Cancers
ASTRO guideline sets standard for use of radiotherapy as palliative treatment of pain from bone metastases
Study supports earlier colon cancer screening for men, but not African Americans
Bone marrow procedures move into the 21st century
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
